REVVITY INC. DL 1/ US7140461093 /
| 2024-06-01 1:03:55 PM | Chg. 0.00 | Volume | Bid1:03:55 PM | Ask1:03:55 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 99.92EUR | 0.00% | - Turnover: - |
99.92Bid Size: - | 101.55Ask Size: - | 12.43 bill.EUR | - | - |
GlobeNewswire
05-28
Standard BioTools Purchases the Carterra® LSA-XT System to Accelerate Data Delivery and Provide Grea...
GlobeNewswire
05-09
Curia and Carterra Partner on Biologics Symposium to Further Biotechnology Research in the Pacific N...
GlobeNewswire
01-19
Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Pan...
GlobeNewswire
01-08
Pleno Deploys its RAPTOR Instrument Platform Available with TotalSeq™ Antibodies from BioLegend
GlobeNewswire
2023-11-30
Study Shows that OGM Plays an Important Role in Efficient Diagnosis of FSHD
GlobeNewswire
2023-11-13
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revvity, Inc. -...
GlobeNewswire
2023-11-05
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revvity, Inc. - ...
GlobeNewswire
2021-05-18
Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test is Used in the UK COVID-19 Human Challenge Study...
GlobeNewswire
2021-05-11
Oxford Immunotec’s T-SPOT.COVID Test is Used in the COV-AD Clinical Study to Investigate the Immunol...
GlobeNewswire
2021-04-29
Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test Used in DIRECT Study to Investigate the T Cell R...
